EXCEL decision analytic model we considered disease incidence and sequelae, serotype coverage and health care utilization to compare costs and impact of PCV13 vs. PCV10, vs. PCV7 and vs. no vaccination on invasive pneumococcal disease (IPD), pneumonia, and otitis media, among vaccinated children (direct effects only) and the entire population while including indirect (herd) effects. Epidemiological data from Greek published studies and the National Statistical Service were supplemented by expert panel opinion and international literature. Published costs from the Athens University Paediatric Hospital and government price bulletins were employed, assuming price parity between PCV7 and PCV13. Only hospital treatment costs were con-considered and outcomes were discounted at 3%.
infection through screening and treatment of eligible patients has the potential to contribute to secondary prevention of HBV. We assessed the costs-effectiveness of systematic screening for chronic hepatitis B (CHB) of first generation migrants in The Netherlands from intermediate and high endemic countries. METHODS: Epidemiological data of expected numbers of patients with active CHB in the target population and data on the costs of a screening program were combined with the outcomes of a Markov model in terms of costs and QALYs for patients with and without treatment, using a life time horizon. The base-case assumptions were an HBV prevalence of 3.35%, 35% participation in screening, specialist consultation for 58% of patients selected for referral, and 75% of eligible patients starting treatment. RESULTS: Compared to the status quo, a one-time screening can reduce mortality of liver related diseases by 10%, from 1073 to 965 deaths. Using base case estimates, the incremental cost effectiveness ratio (ICER) of screening compared to the status quo is a8966 per QALY gained. The ICER varied between a7,936 and a11,705 per QALY gained in univariate sensitivity analysis, varying parameter values of HBV prevalence, participation rate, successful referral and treatment compliance. In multivariate sensitivity analysis for treatment effectiveness the ICER varied between a7,222 and a15,694, and for disease progression in natural history from a5,568 to a60,418. CONCLUSIONS: Early detection and treatment of eligible patients has a large impact on liver related health outcomes. A systematic screening program for chronic HBV infection targeted at first generation migrants is likely to be cost effective, even at low estimates for the HBsAg prevalence, participation, referral and treatment compliance. To determine the cost effectiveness of Pegatron combination therapy compared with no treatment for Australian patients who have failed an initial attempt at interferon-based (pegylated or non-pegylated) therapy. METHODS: The structure of the Markov model, utility values and transition probabilities were based on the literature. SVR and virologic response rates by genotype and fibrosis were obtained from EPIC3 (Evaluation of PegIntron in Control of Hepatitis C Cirrhosis). EPIC3 is a large, prospective, multiphase clinical program evaluating the retreatment of chronic Hepatitis C patients with significant fibrosis/cirrhosis in whom previous treatment with nonpegylated or PEG-IFN alfa plus ribavirin was ineffective (ie, patients experienced virologic nonresponse or relapse). Resource utilization was determined by a modified Delphi approach for various CHC health states. The population parameters used in the model reflect the mix of moderate and cirrhotic patients infected with different HCV genotypes, local medical management protocols, liver transplantation rates, and age-specific mortality rates of CHC patients in Australia. RESULTS: In the trial (N 1336), SVR was achieved by 22.6% (99% CI 19.7-25.6) of subjects. Of the 499 subjects with undetectable HCV-RNA viral load after 12 weeks of treatment, 56.5% (95% CI 52.2-60.9) achieved an SVR. After discounting of costs and outcomes and extending to a life-time model, the modelled ICER was $12,887 Australian dollars per QALY gained. Sensitivity analyses indicated that when parameters are varied across reasonable ranges of their base case values, the ICER ratios range from cost saving to less than $50,000 per QALY gained. CONCLUSIONS: Based on clinical evidence, Pegatron treatment for patients who have failed prior interferon alfa combination therapy is highly cost-effective relative to no treatment. Thus, allowing one course of retreatment for individuals who have failed an initial attempt at interferon alfa-based therapy is a cost effective approach to preventing further extension of the Hepatitis C epidemic in Australia.
PIN37 COST EFFECTIVENESS OF PEGYLATED-INTERFERON

PIN38 COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE
Kang HY 1 , Kim HS 1 , Choi JY 1 , Kim YH 2 1 Yonsei University, Seoul, South Korea, 2 University of Ulsan, Seoul, South Korea OBJECTIVES: To assess the cost-effectiveness of palivizumab as a preventive treatment against respiratory syncytial virus (RSV) infection in children with congenital heart disease (CHD) in Korea. METHODS: A decision analytic model was developed to determine cost-effectiveness of prophylaxis with 5 monthly doses of palivizumab injection as compared to no prophylaxis. The analysis was based on a lifetime followup period to capture the impact of palivizumab on long-term morbidity and mortality resulting from RSV infection. Efficacy of prophylaxis was measured as the number of RSV hospitalizations and mortality avoided, and derived from literature. Prophylaxis cost was defined as a sum of drug acquisition costs and costs associated with outpatient visits occurred to receive palivizumab injection. Average cost for a hospitalization with RSV was calculated on the basis of 40 confirmed cases of RSV hospitalization occurred between 2006 and 2008 from the two hospitals participated in this study. Future costs and effectiveness were discounted at 5%. RESULTS: In children with CHD, prophylaxis with palivizumab compared with no prophylaxis had an incremental cost-effectiveness ratio of 12.0 million Korean won (KW, 1 US dollar is approximately equal to 1000 KW) per life year gained (LYG) and 6.9 million KW per LYG from payer's and societal perspective, respectively. One-way sensitivity analyses and scenario analysis confirmed the robustness of the model. CONCLUSIONS: The estimated ICER of palivizumab is within the generally accepted willingness-to-pay threshold of ICER in Korean society. Thus, the use of palivizumab is considered cost-effective in children with CHD in Korea. The epidemiology of varicella and consequences of implementing different vaccination programs were investigated using an age-structured dynamic model. The basecase assumed one dose protects for 17 years and two doses for three times longer and no natural immunity boosting. MMRV vaccination was assumed to replace up to 80% of MMR over 5 years. An alternative scenario was analysed to assess the impact of an improved MMRV vaccination coverage (replacement of 100% of MMR over a 2-year period plus a catch up program for eight years in 5-year olds). A MMRV vaccine price of a54 per dose was assumed. RESULTS: In the basecase, varicella incidence decreased from 12,707 per million person-years before vaccination to 4,746 after 30 years of vaccination (steady state). With fewer varicella cases and associated complications, annual outpatient and hospital costs decrease by 32%. The cost per qualityadjusted life year (QALY) gained after 30 years was a3347 (95%CI 1; 9927). With the scenario of improved vaccination coverage, varicella incidence decreased to 2,085 per million person-years and the cost per QALY was estimated at a3284 (95%CI 15; 8916) after 30 years of vaccination. If a societal perspective is considered (including lost productivity costs), both the basecase and alternative vaccination scenario produced more QALYs and cost-savings. CONCLUSIONS: Gradual and partial replacement of MMR with MMRV vaccination is predicted to dramatically decrease varicella incidence, and, to be highly cost-effective from a payer perspective and cost-saving from a societal perspective. A more intensive MMRV coverage is predicted to further reduce varicella incidence while remaining a highly cost-effective vaccination strategy.
PIN39 COST-EFFECTIVENESS OF MASS VARICELLA VACCINATION IN FRANCE: ECONOMIC CONSEQUENCES OF AN INTENSIVE VACCINATION PROGRAM
PIN40 COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO
Soto-Molina H, Celaya JM, Hernandez Guerrero N, Castillejos C Janssen Cilag, Mexico, Mexico OBJECTIVES: To Demonstrate that doripenem is a cost-effective option compared with the most utilized treatments in patients with Ventilator-Associated Pneumonia (VAP) in Mexico, from the point of view of the Mexican Institute of Social Security (IMSS). METHODS: A decision tree was elaborated for patients with VAP. Patients were assumed to be treated with doripenem, imipenem or piperacilin-tazobactam (PT)
